Mark S. Schroeder Sells 188 Shares of Laboratory Corp. of America Holdings (NYSE:LH) Stock

Laboratory Corp. of America Holdings (NYSE:LH) EVP Mark S. Schroeder sold 188 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $188.49, for a total transaction of $35,436.12. Following the completion of the sale, the executive vice president now directly owns 533 shares of the company’s stock, valued at approximately $100,465.17. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Mark S. Schroeder also recently made the following trade(s):

  • On Monday, February 10th, Mark S. Schroeder sold 108 shares of Laboratory Corp. of America stock. The shares were sold at an average price of $181.99, for a total transaction of $19,654.92.

Shares of Laboratory Corp. of America stock traded up $0.55 on Friday, hitting $195.28. The company had a trading volume of 624,203 shares, compared to its average volume of 701,471. The firm has a market capitalization of $17.82 billion, a P/E ratio of 25.69, a P/E/G ratio of 1.81 and a beta of 1.07. Laboratory Corp. of America Holdings has a twelve month low of $140.53 and a twelve month high of $196.36. The company has a debt-to-equity ratio of 0.93, a current ratio of 1.17 and a quick ratio of 1.08. The stock has a 50-day moving average of $176.75 and a 200-day moving average of $170.23.

Laboratory Corp. of America (NYSE:LH) last released its quarterly earnings results on Thursday, February 13th. The medical research company reported $2.86 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.80 by $0.06. Laboratory Corp. of America had a net margin of 6.63% and a return on equity of 15.33%. The company had revenue of $3 billion during the quarter, compared to analysts’ expectations of $2.92 billion. During the same quarter in the prior year, the company earned $2.52 earnings per share. The business’s quarterly revenue was up 7.6% compared to the same quarter last year. Equities analysts predict that Laboratory Corp. of America Holdings will post 11.25 EPS for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in LH. NuWave Investment Management LLC boosted its holdings in Laboratory Corp. of America by 558.8% during the third quarter. NuWave Investment Management LLC now owns 639 shares of the medical research company’s stock worth $107,000 after purchasing an additional 542 shares during the last quarter. Wealthfront Advisers LLC boosted its holdings in Laboratory Corp. of America by 3.1% during the third quarter. Wealthfront Advisers LLC now owns 2,054 shares of the medical research company’s stock worth $345,000 after purchasing an additional 62 shares during the last quarter. DNB Asset Management AS boosted its holdings in Laboratory Corp. of America by 0.6% during the third quarter. DNB Asset Management AS now owns 10,579 shares of the medical research company’s stock worth $1,777,000 after purchasing an additional 64 shares during the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd boosted its holdings in Laboratory Corp. of America by 8.1% during the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 13,000 shares of the medical research company’s stock worth $2,184,000 after purchasing an additional 970 shares during the last quarter. Finally, Signaturefd LLC boosted its holdings in Laboratory Corp. of America by 27.3% during the third quarter. Signaturefd LLC now owns 970 shares of the medical research company’s stock worth $163,000 after purchasing an additional 208 shares during the last quarter. Institutional investors and hedge funds own 90.74% of the company’s stock.

LH has been the subject of several recent analyst reports. Zacks Investment Research raised shares of Laboratory Corp. of America from a “sell” rating to a “hold” rating and set a $186.00 target price for the company in a research note on Monday, January 13th. UBS Group reduced their price target on shares of Laboratory Corp. of America from $204.00 to $200.00 and set a “buy” rating for the company in a report on Monday, October 21st. Citigroup upped their price target on shares of Laboratory Corp. of America from $179.00 to $204.00 and gave the company a “neutral” rating in a report on Friday. Bank of America cut shares of Laboratory Corp. of America from a “neutral” rating to an “underperform” rating in a report on Friday, January 3rd. Finally, Piper Sandler upped their price target on shares of Laboratory Corp. of America from to in a report on Thursday. Three equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and eight have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $193.19.

Laboratory Corp. of America Company Profile

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, LabCorp Diagnostics (LCD) and Covance Drug Development. It offers various clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually-transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests.

See Also: Outstanding Shares, Buying and Selling Stocks

Insider Buying and Selling by Quarter for Laboratory Corp. of America (NYSE:LH)

Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.